SGD Pharma announced a strategic Franco-American OEM collaboration with Prince Sterilization Services, to validate Ready-to-Use (RTU) Type I glass primary packaging solutions serving the North American market. The first tangible outcome of this collaboration is the My Sterinity Nasal platform, a new flexible cleaned vial range within SGD Pharma’s My Sterinity RTU platform using the company’s U-Save Type I vials which are designed to support the expanding segment of high-value nasal drug delivery. The launch will be showcased at DCAT Week 2026, taking place from March 23-26 in New York.
My Sterinity Nasal is the first platform to launch from the collaboration between SGD Pharma and Prince, combining SGD Pharma’s leadership in Type I glass manufacture and Prince’s expertise in sterilisation services. Initially available in 3.5, 7.5 and 10 millilitre formats in both clear and amber glass, My Sterinity Nasal vials offer key benefits for high-value nasal therapies:
- Controlled particulate and endotoxin levels for enhanced purity
- Biologically inert Type I sterile glass, with no need for preservatives (reducing inflammation risk)
- Validated Sterility assurance
- Compatibility with standard nasal preservative free pump systems
- Packaged in double-bagged trays for RTU presentation.
The global nasal market is valued at EUR 9 billion with more than 2 billion units, historically dominated by plastic (around 88 percent). However, glass offers greater chemical inertness, barrier protection and long-term bio-compatibility, which is critical for preserving product integrity, minimising adsorption and ensuring sterility in chronic-use therapies.
Once focused on acute, rescue treatments, the nasal market is now expanding more advanced and long-term treatments such as Alzheimer’s, Parkinson’s, multiple sclerosis and depression, that required a primary packaging combining sterility, consistency and precision dosing, making Type I glass the material of choice to safeguard long-term therapeutic stability.